A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer (SGN22E-002)

Brief description of study

The purpose of this study to find out how enfortumab vedotin, when given together with pembrolizumab, cisplatin, carboplatin, or gemcitabine, affects patients with metastatic urothelial cancer. We also want to see how enfortumab vedotin and pembrolizumab combined with cisplatin or carboplatin affect patients with metastatic urothelial cancer. We want to see if the cancer shrinks or disappears with treatment. We also want to find out about the side effects of giving enfortumab vedotin with these drugs.


Clinical Study Identifier: s18-01924
ClinicalTrials.gov Identifier: NCT03288545
Principal Investigator: Arjun Vasant Balar
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.